Price movement over the last 24 hours
ADMA Biologics Inc vs Gigacloud Technology Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Gigacloud Technology Inc trades at $33.67 (market cap $1.23B). The key difference: ADMA Biologics Inc is the larger of the two by market cap, and Gigacloud Technology Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | GCT | |
|---|---|---|
Market Cap | $2.13B | $1.23B |
Sector | Health | Technology |
52-Week High | $20.38 | $51.80 |
52-Week Low | $7.60 | $20.26 |
Enterprise Value | $2.20B | $1.34B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
GigaCloud Technology (GCT) trades at $34.08, up 2.62% with a bullish technical signal and strong fundamentals. The stock shows robust earnings beats, with Q1 2026 EPS of $1.04 exceeding expectations by 20%, and maintains healthy profitability with a 10.77% net margin. Recent news highlights inclusion in TIME's World's Growth Leaders 2026 list and positive analyst coverage, supporting investor confidence.
Outlook remains positive due to undervaluation (P/E 8.64), growth in European markets, and strategic expansions. Risks include potential fiduciary concerns flagged by shareholders and reliance on large parcel merchandise demand. Analyst consensus is 66.7% buy, with a $56 price target from Seeking Alpha on 2026-06-10 suggesting 64% upside.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →